Neuralstem Announces Topline Results Of Phase II ALS Trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- S&P Global shares rise on report of possible CapIQ spinoff
ALS Data Shows Neuralstem (CUR) Approach is 'Risky' - Maxim Group
March 12, 2015 1:13 PM EDTMaxim Group analyst Jason Kolbert weighed in on Neuralstem (NYSE: CUR) after the company reported ALS phase II data this morning.
Kolbert commented, "The press release is worded in a complex way and on the surface appears positive; "7/15 patients may have responded"; however after carefully evaluating the complete press release, it leaves us concerned on several fronts. Multiple injections into the spine is risky and based on our interpretation of the data maybe accelerating the disease. Why so negative? Both... More
Neuralstem (CUR) Announces NSI-566 Phase 2 Met Primary Safety Endpoints
March 12, 2015 6:53 AM EDTNeuralstem (NYSE: CUR) announced top line data from the Phase II trial of NSI-566 spinal cord-derived neural stem cells under development for the treatment of amyotrophic lateral sclerosis (ALS). The study met primary safety endpoints. The maximum tolerated dose of 16 million transplanted cells and the surgery was well tolerated.
Secondary efficacy endpoints at nine months post-surgery indicate a 47% response rate to the stem cell treatment, as measured by either near-zero slope of decline or positive slope of ALSFRS score in seven out of 15 patients and by either a near-zero decline, or positive... More
